Navigation Links
Access Highlighted in Recent BusinessWeek Article
Date:9/11/2007

DALLAS, Sept. 11 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that renowned business columnist Gene Marcial of BusinessWeek, highlighted Access Pharmaceuticals in the most recent edition dated September 17, 2007. The article is also available on http://www.BusinessWeek.com under the 'Inside Wall Street' column.

The article focused upon the major opportunity Access' lead compound, ProLindac, has to offer shareholders. ProLindac, a platinum-based drug that is currently in Phase II clinical trials for ovarian and colorectal cancer, has the potential to be a next generation cancer therapy, which is currently dominated by Eloxatin, a current platinum drug that produces revenues in excess of $2 billion and is close to patent expiration in the U.S. Marcial also noted that Dr. Esteban Cvitkovic, Access' Vice-Chairman (Europe) and Senior Director, Oncology Clinical R&D, was responsible for developing Eloxatin during his tenure at Sanofi-Aventis. The article references certain products of Somanta Pharmaceuticals in the cancer area. While Access has executed a definitive merger agreement with Somanta, the acquisition has not yet closed and the closing is still subject to the satisfaction of the closing conditions set forth in the merger Agreement. The consummation of the acquisition is subject to numerous closing conditions.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery. Access has announced the execution of a definitive merger agreement to acquire Somanta. The acquisition of Somanta has not yet closed and the closing is subject to numerous closing conditions. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: Access' plans to initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success, its ability to successfully develop marketed products and the ability to obtain or meet the closing conditions in the merger agreement with Somanta Pharmaceuticals, Inc. and applicable regulatory and tax requirements, and to otherwise complete the merger in a timely manner, yet there can be no assurances that the closing conditions will be met or waived or that the transaction will close. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing and to the risks detailed in Access' and Somanta's Annual Reports on Form 10-KSB and other reports filed by Access and Somanta with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Research explains why women lack equal access to angel capital
2. Abbott vs. Thailand has implications for innovation and access
3. More access points for Madison wireless
4. GE partner allows real-time access to patient data
5. Broadband access needs a champion, FCC commissioner says
6. UW Trace center makes sending packages accessible to all
7. Green Bay area businesses ramp up wireless access
8. GE Healthcare, MobileAccess to collaborate on hospital wireless
9. Stem-cell debate, wireless access and other endeavors heat up
10. Computer access brings more Wisconsinites to libraries
11. Promega to get early access to WARF technologies under new agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... San Francisco, CA (PRWEB) , ... May 03, ... ... Morf Playbook™ enterprise talent development, skill-building and compliance training platform on ... Direct training course: Overview of Regulatory Requirements for Medical Devices. The course ...
(Date:5/3/2016)... ... May 03, 2016 , ... Wearable Tech + ... conferences, will take place on June 7-8, 2016, at the New York Academy of ... incorporating technology -- including AR/VR, machine learning, apps, robotics and AI -- throughout a ...
(Date:5/2/2016)... , May 2, 2016 ... that its technology partner Mannin Research Inc. will be ... (ARVO), which takes place from May 1-5, 2016 in ... will be meeting with its vendors and research partners. ... business development goals and other collaborative opportunities for the ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... leader in personalized pain medicine, is excited to announce the launch of the ... supporting public health studies, volunteerism, and education to promote the use of personalized ...
Breaking Biology Technology:
(Date:3/18/2016)... , March 18, 2016 ... Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure ... & security companies in the border security market and the ... and Europe has led visiongain ... companies improved success. --> defence & security ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... http://www.apimages.com ) - --> - Renvoi : ... - --> --> ... solutions biométriques, fournit de nouveaux lecteurs d,empreintes digitales ... LF10 de DERMALOG sera utilisé pour produire des ...
(Date:3/9/2016)... , March 9, 2016 This BCC ... future states of the RNA Sequencing (RNA Seq) market ... such as instruments, tools and reagents, data analysis, and ... various segments of the RNA-Sequencing market such as RNA-Sequencing ... Identify the main factors affecting each segment and forecast ...
Breaking Biology News(10 mins):